



## Dopamine in Health and Disease 2.0

Guest Editor:

**Prof. Dr. Marc Ekker**

Department of Biology, Faculty of  
Science, University of Ottawa,  
Ottawa, ON K1N 6N5, Canada

Deadline for manuscript  
submissions:

**closed (31 October 2023)**

### Message from the Guest Editor

Dear Colleagues,

The neurotransmitter dopamine plays crucial roles within the central nervous system, influencing multiple neural pathways and associated behaviors such as locomotion, reward mechanisms, neuroendocrine control, and emotion, to name but a few. Dysfunction of dopamine systems, including degeneration of dopamine neurons, is associated with numerous diseases. Some of the medications used to treat these diseases act by altering the effects of dopamine. This Special Issue on “Dopamine in Health and Disease 2.0” will present a selection of original research papers or reviews that address such topics as cellular mechanisms of disease affecting dopaminergic systems, genetic influences on dopamine neuron health and function, animal models of dopamine neuron loss and regeneration, and novel therapeutics for pathologies that involve dopamine neurons.

Prof. Dr. Marc Ekker

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI